ArticleFuture oncology (London, England)2025

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.

Thomas Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.